Cyclo Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYTH research report →
About the company
Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions. Its flagship therapeutic candidate, Trappsol Cyclo, holds orphan drug status and is presently in Phase III clinical trials targeting Niemann-Pick Type C disease.
- CEO
- N. Scott Fine
- IPO
- 2000
- Employees
- 8
- HQ
- Gainesville, FL, US
Price Chart
- Market Cap
- $23.59M
- P/E
- -0.59
- P/S
- 21.92
- P/B
- 2.47
- EV/EBITDA
- -0.77
- Div Yield
- 0.00%
- Gross Margin
- 90.85%
- Op Margin
- -1862.69%
- Net Margin
- -1863.36%
- ROE
- -730.48%
- ROIC
- -294.82%
- Revenue
- $1.08M · -21.76%
- Net Income
- $-20,057,302 · -31.27%
- EPS
- $-1.23 · 32.04%
- Op Income
- $-20,050,057
- FCF YoY
- -6.99%
- 52W High
- $1.62
- 52W Low
- $0.55
- 50D MA
- $0.80
- 200D MA
- $0.83
- Beta
- -0.57
- Avg Volume
- 1.76M
Get TickerSpark's AI analysis on CYTH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 27, 25 | CONKLING WILLIAM | other | 27,654 |
| Feb 27, 25 | Wong Vivien | other | 25,140 |
| Feb 27, 25 | Cross Shawn | other | 28,597 |
| Feb 27, 25 | Toig Randall M. | other | 33,311 |
| Feb 27, 25 | STRATTAN CE RICK | other | 30,169 |
| Feb 27, 25 | Ostronic Francis Patrick | other | 70,329 |
| Feb 27, 25 | Sieger Markus | other | 58,138 |
| Feb 27, 25 | SHANAHAN WILLIAM S | other | 25,140 |
| Dec 23, 24 | Rafael Holdings, Inc. | other | 3,968,254 |
| Nov 15, 24 | CONKLING WILLIAM | other | 16,660 |
Our CYTH coverage
Recent articles, reports, and earnings notes.
No research on CYTH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CYTH report →Similar companies
Peers in the same neighborhood.